Pharmacogenomics of Pediatric Cardiac Arrest: Cisplatin Treatment Worsened by a Ryanodine Receptor 2 Gene Mutation

In thelast few decades, the roles of cardio-oncology and cardiovascular geneticsgained more attention in research daily clinical practice, shaping a new approach management patients affected by cancer disease. Genetic characterization undergoing treatment can support better risk stratification beyond typical factors, suchas contractile function QT interval duration, uncovering possible patient’s concealed predisposition to heart failure, life threatening arrhythmias sudden death. Specifically, an integrated cardiogenetic oncological practice ensure best patient-centered healthcare model, suggesting, also adequate cardiac monitoring timing alternative treatments, reducing drug-related complications. We report case 14-month-old girl neuroblastoma, treated cisplatin, complicated arrest. described genetic Ryanodine receptor 2 (RYR2) gene mutation subsequent pharmacogenomic shape treatment.